Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone extended-release - GlaxoSmithKline

Next Previous
Search
Drug Profile

Testosterone extended-release - GlaxoSmithKline

Alternative Names: T-8 oral testosterone - GlaxoSmithKline; Testosterone-extended-release

Latest Information Update: 13 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; University of Washington
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypogonadism

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypogonadism(In volunteers) in USA (PO, Controlled release)
  • 01 Jun 2012 GlaxoSmithKline completes a phase I trial in volunteers in USA (NCT01167829)
  • 27 Oct 2010 GlaxoSmithKline completes enrolment in a phase I trial in volunteers in USA (NCT01167829)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top